Wells Fargo Gives a Hold Rating to Amgen (AMGN)
In a report released today, Mohit Bansal from Wells Fargo assigned a Hold rating to Amgen, with a price target of $390.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bansal covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and Eli Lilly & Co. According to TipRanks, Bansal has an average return of 9.2% and a 55.65% success rate on recommended stocks.
In addition to Wells Fargo, Amgen also received a Hold from Bernstein’s Courtney Breen in a report issued on March 30. However, on March 26, Piper Sandler reiterated a Buy rating on Amgen (NASDAQ: AMGN).
Based on Amgen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $9.9 billion and a net profit of $1.33 billion. In comparison, last year the company earned a revenue of $9.09 billion and had a net profit of $627 million
Read More on AMGN:
Disclaimer & DisclosureReport an Issue
- FDA identifies cases of serious liver injury in patients taking Tavneos
- Amgen announces data on Repatha from Phase 3 Vesalius-CV trial
- Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy
- Amgen Expands Oncology Pipeline With New Phase 1 AMG 436 Study in MSI-H/dMMR Tumors
- Vertex Pharmaceuticals price target raised to $550 from $515 at Wells Fargo
